Crispr Therapeutics AG: "Here's the problem: that's a momentum stock, and right now, momentum is out of favor so I cannot necessarily recommend that Crispr is the place to be."
Spectrum Pharmaceuticals: "No, man. If you're going to do that, you want to go high end. I want you [in] Amgen, which my charitable trust owns. Amgen's got this drug, Aimovig, which is taking the world by storm. It's an anti-migraine drug. Amgen is the one you want."